학술논문
Neurologic Safety Monitoring of COVID-19 Vaccines: Lessons From the Past to Inform the Present.
Document Type
Academic Journal
Author
Thakur KT; From the Department of Neurology, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York. ktt2115@cumc.columbia.edu.; Epstein S; From the Department of Neurology, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York.; Bilski A; From the Department of Neurology, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York.; Balbi A; From the Department of Neurology, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York.; Boehme AK; From the Department of Neurology, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York.; Brannagan TH; From the Department of Neurology, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York.; Wesley SF; From the Department of Neurology, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York.; Riley CS; From the Department of Neurology, Columbia University Irving Medical Center and New York Presbyterian Hospital, New York.
Source
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE
Subject
Language
English
Abstract
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a global effort to rapidly develop and deploy effective and safe coronavirus disease 2019 (COVID-19) vaccinations. Vaccination has been one of the most effective medical interventions in human history, although potential safety risks of novel vaccines must be monitored, identified, and quantified. Adverse events must be carefully assessed to define whether they are causally associated with vaccination or coincidence. Neurologic adverse events following immunizations are overall rare but with significant morbidity and mortality when they occur. Here, we review neurologic conditions seen in the context of prior vaccinations and the current data to date on select COVID-19 vaccines including mRNA vaccines and the adenovirus-vector COVID-19 vaccines, ChAdOx1 nCOV-19 (AstraZeneca) and Ad26.COV2.S Johnson & Johnson (Janssen/J&J).
(© 2021 American Academy of Neurology.)
(© 2021 American Academy of Neurology.)